<DOC>
	<DOCNO>NCT01959971</DOCNO>
	<brief_summary>Primary Objective : To assess effect subcutaneous ( SC ) dose alirocumab elimination ( measure Fractional Clearance Rate ( FCR ) ) apolipoprotein B ( apoB ) low density lipoprotein ( LDL ) adult mildly elevate LDL-cholesterol ( LDL-C ) . Secondary Objectives : To assess effect SC dose alirocumab : - Various parameter metabolism turnover plasma different lipoprotein - Plasma lipids concentration : total cholesterol , high density lipoprotein cholesterol ( HDL-C ) , triglyceride , low density lipoprotein cholesterol ( LDL-C ) , apoB , lipoprotein ( ) ( Lp ( ) ) - Lipoprotein particle size profile - PCSK9 ( free total ) concentration serum To assess safety tolerability alirocumab . To assess emergence anti-alirocumab antibody . To document serum alirocumab concentration .</brief_summary>
	<brief_title>Effect Alirocumab Lipid Metabolism Adults With Elevated LDL-Cholesterol</brief_title>
	<detailed_description>Total duration study per subject 26 week , include screen period ≤ 4 week , placebo treatment period 4 week , alirocumab treatment period 10 week , follow period 8 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Generally healthy ; LDLC level serum plasma ≥ 100 mg/dL &lt; 190 mg/dL Screening . Exclusion criterion : LDLC ≥ 160 mg/dL Screening 2 major Coronary Heart Disease risk factor , define National Cholesterol Education Program guideline . Receiving treatment kind hyperlipidemia within 6 week enrollment . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>